|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 90 No. 8 (October 15), 1997:
pp. 3067-3072
An In Vitro Analysis of the Combination of Hemophilia A and Factor VLEIDEN
By
Cornelis van `t Veer,
Neal J. Golden,
Michael Kalafatis,
Paolo Simioni,
Rogier M. Bertina, and
Kenneth G. Mann
From the Department of Biochemistry, University of Vermont, Burlington, VT; the Institute of Medical Semeiotics, University of Padua, Padua, Italy; and the Hemostasis and Thrombosis Research Center, University Hospital, Leiden, The Netherlands.
 |
ABSTRACT |
The classification of factor VIII deficiency, generally used based on plasma levels of factor VIII, consists of severe (<1% normal factor VIII activity), moderate (1% to 4% factor VIII activity), or mild (5% to 25% factor VIII activity). A recent communication described four individuals bearing identical factor VIII mutations. This resulted in a severe bleeding disorder in two patients who carried a normal factor V gene, whereas the two patients who did not display severe hemophilia were heterozygous for the factor VLEIDEN mutation, which leads to the substitution of Arg506  Gln mutation in the factor V molecule. Based on the factor VIII level measured using factor VIII-deficient plasma, these two patients were classified as mild/moderate hemophiliacs. We studied the condition of moderate to severe hemophilia A combined with the factor VLEIDEN mutation in vitro in a reconstituted model of the tissue factor pathway to thrombin. In the model, thrombin generation was initiated by relipidated tissue factor and factor VIIa in the presence of the coagulation factors X, IX, II, V, and VIII and the inhibitors tissue factor pathway inhibitor, antithrombin-III, and protein C. At 5 pmol/L initiating factor VIIa.tissue factor, a 10-fold higher peak level of thrombin formation (350 nmol/L), was observed in the system in the presence of plasma levels of factor VIII compared with reactions without factor VIII. Significant increase in thrombin formation was observed at factor VIII concentrations less than 42 pmol/L (~6% of the normal factor VIII plasma concentration). In reactions without factor VIII, in which thrombin generation was downregulated by the addition of protein C and thrombomodulin, an increase of thrombin formation was observed with the factor VLEIDEN mutation. The level of increase in thrombin generation in the hemophilia A situation was found to be dependent on the factor VLEIDEN concentration. When the factor VLEIDEN concentration was varied from 50% to 150% of the normal plasma concentration, the increase in thrombin generation ranged from threefold to sevenfold. The data suggested that the analysis of the factor V genotype should be accompanied by a quantitative analysis of the plasma factor VLEIDEN level to understand the effect of factor VLEIDEN in hemophilia A patients. The presented data support the hypothesis that the factor VLEIDEN mutation can increase thrombin formation in severe hemophilia A.
| |
INTRODUCTION |
IN NORMAL HOMEOSTASIS, the procoagulant system is in balance with the anticoagulant and fibrinolytic systems. The procoagulant reaction starts with the binding of plasma factor VIIa to tissue factor (TF ). The membrane-bound factor VIIa.TF enzyme complex activates the zymogens factor X and factor IX by limited proteolysis.1 Factor IXa combines with factor VIIIa on a phospholipid surface, forming the intrinsic tenase that generates additional factor Xa. Factor Xa associates with factor Va on a phospholipid membrane surface to form prothrombinase, which activates prothrombin to thrombin. (For reviews on blood coagulation and membrane-dependent reactions in blood coagulation see, respectively, Davie et al2 and Mann et al.3 ) The anticoagulant system consists of several stoichiometric protease inhibitors including the tissue factor pathway inhibitor (TFPI),4 antithrombin-III (AT-III),5 heparin cofactor-II,6 and the dynamic protein C pathway, which involves thrombin, protein C, protein S, and thrombomodulin. The negative feedback mechanism provided by the protein C pathway is initiated by the binding of thrombin to thrombomodulin and the activation of protein C by the thrombin/thrombomodulin complex. (For a review on thrombomodulin and protein C see Esmon.7 ) Activated protein C (APC) is thought to exert its inhibitory effect on coagulation by proteolytically inactivating the cofactors of prothrombinase and intrinsic tenase, factor V(a) and factor VIII(a), respectively.8-14
Defects in the procoagulant or anticoagulant systems by a single point mutation may result in a bleeding disorder or thrombosis, respectively. In these cases variability in the phenotypic expression (ie, the presence or the degree of the disease) among individuals carrying identical genetic mutations is frequently observed. In some cases such variability may be ascribed to the coinheritance of another mutation in the same or another gene. For example, coinheritance of both factor XI and factor VIII deficiencies results in a more severe bleeding tendency than that associated with either deficiency alone.15 Examples of increased thrombotic risk by the combination of heterozygous inheritance are the factor VLEIDEN mutation with either protein C16 or protein S17 deficiency, which explains some of the variation observed in thrombotic risk associated with the heterozygous deficiencies. We have recently analyzed in an in vitro model the consequences of the coexistence of factor VLEIDEN with protein CVermont.18 This resulted in a stable factor Va molecule, which would predict excessive thrombin generation in individuals bearing those two mutations. Conversely we speculated that factor VLEIDEN might be beneficial in the case of hemophilia A by prolonging thrombin formation.18 Subsequently, Nichols et al19 described hemophilic patients who displayed the phenotype of moderate hemophilia A with a factor VIII genotype, which is ordinarily associated with severe hemophilia. Two individuals with less severe disease carried the G to A mutation in the factor V gene,19 which is responsible for the Arg506 Gln substitution, which results in the APC-resistant factor VLEIDEN.20-22 Hence, the factor VLEIDEN mutation seems to have the potential to compensate for a defect in the factor VIII molecule in vivo. In this study we recreate, in vitro, the condition of moderate to severe hemophilia A combined with the factor VLEIDEN mutation in a reconstituted model of the TF pathway to thrombin.23-25 The data obtained with this model provided experimental biochemical support for the hypothesis that the factor VLEIDEN mutation can increase thrombin formation in hemophilia A.
| |
MATERIALS AND METHODS |
Reagents.
Phosphatidylserine (PS) from bovine brain, phosphatidylcholine (PC) from egg yolk, and HEPES were purchased from Sigma (St Louis, MO). D-phenylalanyl-L-arginine chloromethyl ketone (FPR-ck) was a gift from Dr R. Jenny (Haematologic Technologies Inc, Essex Jct, VT). Spectrozyme TH was purchased from American Diagnostica (Greenwich, CT).
Proteins.
Human coagulation factors X and IX and prothrombin were isolated from fresh frozen plasma using the general methods of Bajaj et al26 and were depleted from contaminants and traces of active enzymes as described elsewhere.24 Human protein C was purified and treated with FPR-ck as described.25 Human factor V was isolated from freshly frozen human plasma by using the method of Nesheim et al.27 Human factor VLEIDEN was isolated as described22 from citrated plasma of patients, which were found to be homozygous for the mutation by DNA analysis.21 Human AT-III was purified as described by Griffith et al.28 Recombinant factor VIII and recombinant TF (residues 1-242) were provided as gifts from Drs Shu Len Liu and Roger Lundblad (Hyland division, Baxter Healthcare Corp, Duarte, CA). Recombinant human coagulation factor VIIa was purchased from NOVO Pharmaceuticals. Recombinant soluble thrombomodulin (Solulin) was provided as a gift from Dr J. Morser (Berlex, Richmond, CA). Recombinant full-length TFPI produced in Escherichia coli was provided as a gift from Dr K. Johnson (Chiron Corp, Emeryville, CA).
Coagulation activation experiments.
Thrombin generation initiated by factor VIIa.TF in a reconstituted procoagulant model using mean plasma protein concentrations was studied as described previously.23 TF was relipidated into 400 µmol/L phospholipid vesicles, composed of 75% PC and 25% PS, for 30 minutes at 37°C in 20 mmol/L HEPES, 150 mmol/L NaCl, 2 mmol/L CaCl2 pH 7.4 (HEPES/Ca2+). The relipidated TF was incubated with factor VIIa for 20 minutes at 37°C to allow factor VIIa.TF complex formation. Factor V and factor VIII were added in microliter amounts of concentrated stock solutions to the equilibrated factor VIIa.TF mixture (total volume of addition not exceeding 0.25% of the final reaction volume), and immediately thereafter the reaction was started by the addition of a solution containing factor X, factor IX, and prothrombin, which was prepared in HEPES/Ca2+. The zymogen solution was preheated at 37°C for 3 minutes before addition to the factor VIIa.TF, factor V, and factor VIII mixture. When TFPI, AT-III, or protein C were included, they were added to the factor X, factor IX, and prothrombin mixture. Thrombomodulin was added to the factor VIIa.TF mixture.
The final concentrations of the proteins in the reaction chosen to represent mean plasma values are 160 nmol/L factor X, 90 nmol/L factor IX, 0.7 nmol/L factor VIII, 20 nmol/L factor V, 1.4 µmol/L prothrombin, 2.5 nmol/L TFPI, 3.4 µmol/L AT-III, and 65 nmol/L protein C. The TF concentration was varied to change the concentration of the initiator complex while factor VIIa was kept constant and in substantial excess at 0.1 nmol/L. Final phospholipid concentration was 200 µmol/L. After initiation of the reaction, aliquots were withdrawn from the reaction mixture and quenched in 20 mmol/L EDTA, 20 mmol/L Tris, 150 mmol/L NaCl, pH 7.4, containing 0.4 mmol/L Spectrozyme TH and assayed immediately for thrombin activity. The hydrolysis of the substrate was monitored by the change in absorbance at 405 nm using a Vmax spectrophotometer (Molecular Devices Corp, Menlo Park, CA). Thrombin generation was calculated from a standard curve prepared by serial dilutions of  -thrombin.
| |
RESULTS |
Factor VIII titration at 5 pmol/L factor VIIa.TF.
A factor VIII titration was performed in the reconstituted procoagulant model with only the stoichiometric inhibitors TFPI and AT-III present at their respective plasma concentration. Previously we found that in the presence of this combination of inhibitors the explosive propagation phase of thrombin generation becomes a threshold-limited event with respect to the initiating factor VIIa.TF concentration.24 Figure 1 displays thrombin generation in mixtures containing varying amounts of factor VIII initiated by the addition of 1 pmol/L or 5 pmol/L factor VIIa.TF. At 1 pmol/L VIIa.TF in the presence of 0.7 nmol/L factor VIII (100%; open circles), significant thrombin generation was not observed for up to 8 minutes in the reaction. After 8 minutes, thrombin generation occurred slowly and reached a level of 10 nmol/L at 14 minutes, a level that was observed to remain constant until 20 minutes into the reaction. At 1 pmol/L factor VIIa.TF in the absence of factor VIII (open triangles), no significant thrombin was generated in the 20-minute period evaluated. In marked contrast, at 5 pmol/L factor VIIa.TF and 0.7 nmol/L factor VIII (solid circles), significant thrombin generation occurs. After the first 30 seconds, in which 12 nmol/L enzyme is formed, thrombin generation proceeds with a maximal rate of ~210 nmol/L/min. The maximum level (350 nmol/L) is reached at 3 minutes in the reaction. Subsequently the thrombin level decreases with a t1/2 of ~1.5 minutes, resulting in 18 nmol/L thrombin at 9 minutes. These low levels of thrombin persist up to 20 minutes. The dramatic change in the maximal rate of thrombin generation with only a fivefold change in the initiator concentration from 1 to 5 pmol/L illustrates the threshold for explosive thrombin generation under these experimental conditions.
View larger version (21K):
[in this window]
[in a new window]
| Fig 1.
Factor VIII titration at 5 pmol/L factor VIIa.TF. Thrombin formation was initiated by 5 pmol/L factor VIIa.TF in the presence of 0% (solid stars), 3.125% (open squares), 6.25% (solid triangles), 12.5% (open diamonds), 25% (solid squares), 50% (open stars), and 100% (solid circles) of the normal plasma concentration of factor VIII. Thrombin generation is also shown for reactions initiated by 1 pmol/L factor VIIa.TF in the absence (open triangles) or presence of factor VIII (100%, open circles). Data points are the mean of two experiments.
|
|
In reactions initiated by 5 pmol/L factor VIIa.TF in the absence of factor VIII (solid stars) ~12 nmol/L thrombin was generated after 30 seconds; however the reaction did not accelerate after 30 seconds as is the case for reactions containing plasma concentrations of factor VIII. Instead, the thrombin generation rate decreased after 1 minute resulting in 32 nmol/L thrombin at 2 minutes, which persisted over 20 minutes. Reactions at factor VIII concentrations of 3.1% (0.022 nmol/L, open squares) and 6.3% (0.044 nmol/L, solid triangles) displayed only marginal increases of  25% in thrombin generation over that observed in the total absence of factor VIII. In contrast, at 12.5% factor VIII (0.088 nmol/L, open diamonds) a substantial increase (threefold) is observed in the maximum level of thrombin generated (~105 nmol/L). Reactions with factor VIII at 25% (0.175 nmol/L, solid squares) and 50% (0.35 nmol/L, open stars) displayed further increased thrombin generation. However, in these latter reactions the increases in thrombin generation are relatively small compared with that observed at 12.5% factor VIII. At 50% factor VIII the peak thrombin value (180 nmol/L) is 50% that observed in the reaction with a normal plasma factor VIII concentration (0.7 nmol/L).
Effect of the factor VLEIDEN mutation in the absence and presence of the protein C pathway.
Figure 2 displays experiments in which a moderate-severe hemophilia A is mimicked at a factor VIII level of 6% with normal factor V and with factor VLEIDEN. In the absence of protein C and thrombomodulin, thrombin generation is equivalent in the presence of normal factor V (closed circles) and factor VLEIDEN (open circles), and the maximal level of thrombin (~70 nmol/L) is generated at 7 to 10 minutes in the reaction, subsequently the thrombin level declines to ~35 nmol/L at 20 minutes. The lack of an effect of the factor VLEIDEN mutation in the absence of the protein C pathway rules out a direct positive effect of factor VLEIDEN on the reaction.
View larger version (21K):
[in this window]
[in a new window]
| Fig 2.
Effect of the factor VLEIDEN mutation in the absence and presence of the protein C pathway. Thrombin formation is shown for reactions initiated by 5 pmol/L factor VIIa.TF at 6% of the normal plasma concentration of factor VIII in the presence of normal factor V (solid symbols) and factor VLEIDEN (open symbols) in the absence (circles) or presence of protein C and 1 nmol/L thrombomodulin (squares).
|
|
In the presence of protein C (65 nmol/L) and 1 nmol/L soluble thrombomodulin, thrombin generation is initially not influenced with either normal factor V (solid squares) or factor VLEIDEN (open squares). However, after 2 minutes with normal factor V, thrombin generation is downregulated by the protein C pathway with 17 nmol/L thrombin formed. Subsequently, the thrombin level declines to ~6.5 nmol/L at 10 minutes. In contrast, in the presence of factor VLEIDEN, while 18 nmol/L thrombin is formed at 2 minutes, the reaction persists such that a maximal level of 24 nmol/L thrombin is observed at 5 minutes. This thrombin concentration is ~23% higher than for the reaction with normal factor V. Subsequently, the level of thrombin declines in the reaction with factor VLEIDEN to ~13 nmol/L at 10 minutes. The formation-inhibition steady state processes maintain thrombin at this concentration up to 20 minutes. Hence, at 6% factor VIII the thrombin levels generated in the presence of the protein C pathway are twofold higher with factor VLEIDEN in the later phases of the reaction compared with the reaction with normal factor V.
Homozygous and heterozygous factor VLEIDEN with severe hemophilia A.
The effect of the factor VLEIDEN on thrombin generation in the complete absence of factor VIII is illustrated in Fig 3. Progress curves are shown of thrombin generation for reactions containing protein C and 1 nmol/L thrombomodulin with either 100% normal factor V (solid triangles), with 100% factor VLEIDEN (open circles), or a mixture of 50% normal factor V and 50% factor VLEIDEN (open squares). Thrombin formation is similar in all three reactions for the first 3 minutes, at which time approximately 21 nmol/L thrombin are formed. In the case of normal factor V (triangles) the thrombin level subsequently declines to 6 nmol/L at 12 minutes. In contrast, in the reaction with 100% factor VLEIDEN (open circles), thrombin increases from 21 nmol/L at 3 minutes to 29 nmol/L at 7 minutes. This level of ~29 nmol/L thrombin persists for up to 12 minutes. Subsequently, the thrombin level declines to 13 nmol/L at 20 minutes. Thus, the homozygous phenotype of factor VLEIDEN has the potential to increase thrombin formation in a severe hemophilia A situation almost fivefold. The area under the thrombin generation curve (up to 20 minutes) was 120% larger (2.2-fold) with VLEIDEN compared with normal factor V. In the reaction with 50% normal factor V and 50% factor VLEIDEN (open squares), the thrombin level persists at a concentration of ~20 nmol/L for up to 12 minutes. The thrombin level then declines to 8 nmol/L at 20 minutes. Hence, the heterozygous phenotype of factor VLEIDEN increases thrombin formation in the case of severe hemophilia up to threefold. The area under the thrombin generation curve was 1.9-fold greater than that for the reaction with normal factor V.
View larger version (20K):
[in this window]
[in a new window]
| Fig 3.
Effect of factor VLEIDEN in the case of severe hemophilia A. Thrombin formation in the absence of factor VIII in the presence of protein C and 1 nmol/L thrombomodulin with either normal factor V (triangles), a mixture composed of 50% normal factor V and 50% factor VLEIDEN (squares), or 100% factor VLEIDEN (circles). Thrombin generation was initiated by 5 pmol/L factor VIIa.TF. Error bars represent the standard error of mean (n = 3).
|
|
Effect of a 50% increase in factor V or factor VLEIDEN concentration with severe hemophilia A.
Figure 4 shows the effect of factor V at 30 nmol/L (150% of the normal plasma concentration) in a reaction without factor VIII in the presence of protein C (65 nmol/L) and thrombomodulin (1 nmol/L). This experiment was performed to evaluate whether the beneficial effect of the factor VLEIDEN mutation in hemophilia could be mimicked by increases in normal factor V concentrations within the range observed in normal individuals. The set of experiments shown in Figs 3 and 4 can be compared quantitatively, because they were performed contemporaneously. Thrombin generation in the presence of 30 nmol/L normal factor V results in a small (25% to 40%) increase in thrombin levels formed when compared with the reaction at the normal plasma concentration (20 nmol/L, 100%) of factor V (triangles). At 20 and 30 nmol/L of factor V the thrombin concentration declines with a similar rate after 3 minutes. The area under the thrombin generation curve was 40% higher. Thus, an increase in normal factor V does not result in a very significant enhancement or prolongation of thrombin formation. In contrast, an increase in factor VLEIDEN to 150% of the plasma concentration (Fig 4, open circles) resulted in a threefold increase in the maximum level of formed thrombin compared with the reaction with 100% normal factor V. The area under the thrombin generation curve was 3.75-fold larger. Compared with the reaction with 100% factor VLEIDEN (Fig 3, open circles) the reactions with 150% factor VLEIDEN reached a twofold higher maximum thrombin level and led to a 1.7-fold greater area under curve. The increase in thrombin generation by a 50% increase in factor VLEIDEN is not only higher in an absolute sense compared with the reaction with 100% normal factor V. The relative increases of the reaction with 150% factor VLEIDEN compared with 100% factor VLEIDEN (open circles, Fig 3), which are a 100% increase in maximum thrombin and a 70% increase in area under the curve, are also higher compared with the 25% increase in maximum thrombin and 40% larger area under the curve with a 50% increase in normal factor V. These data show that increases in the concentration of the APC-resistant factor VLEIDEN to the upper range of the normal level will lead to significant amplification and extension of thrombin formation.
View larger version (19K):
[in this window]
[in a new window]
| Fig 4.
Effect of increases in normal factor V and factor VLEIDEN levels in severe hemophilia A. Thrombin formation was initiated under the same conditions as described in Fig 3 in the absence of factor VIII in the presence of either a normal plasma level (100%) of factor V (triangles), 150% factor V (squares), or 150% factor VLEIDEN circles). Error bars represent the standard error of mean (n = 3).
|
|
| |
DISCUSSION |
We have speculated that the factor VLEIDEN phenotype might be beneficial in hemophilia A by partially compensating for a defective factor VIIIa molecule.18 This speculation was apparently verified by the recent report of Nichols et al,19 who reported a varying phenotype (<1% versus 2% to 7% factor VIII activity) for hemophilia A patients with identical genotype. Screening for the factor VLEIDEN mutation showed that two of the patients who had the less severe phenotype also carried the G to A substitution in the factor V gene responsible for the Arg506 Gln mutation, which renders the molecule partially resistant to inactivation by APC. Nichols at al19 hypothesized that the beneficial effect of the factor VLEIDEN mutation could be caused by the extended amplification of the limited signal produced by the defective factor VIII. In this study we recreate these combined hemophilic and thrombophilic phenotypes in a model that reconstitutes the TF pathway to thrombin,23 including the stoichiometric inhibitors TFPI and AT-III24 and the dynamic protein C pathway.25
At an initiating factor VIIa.TF concentration sufficient for explosive thrombin generation at normal concentrations of factor VIII, reduction of the factor VIII concentrations to 6.25% the normal plasma level led to only marginal increases in thrombin generation under these conditions. At 12.5% factor VIII thrombin generation is significantly upregulated compared with the reaction without factor VIII, resulting in a threefold increase in the maximal level of thrombin formed. The significant boundary in thrombin generation between 6.25% and 12.5% factor VIII is analogous to the borderline for the classification of hemophilia patients as mildly (5% to 25% factor VIII activity) or moderately (1% to 4% factor VIII activity) deficient.29 Thus, the model shows a similar factor VIII concentration dependence to that required for adequate hemostasis; the latter inferred from the correlation of factor VIII level with the severity of the hemorrhagic symptoms. When normal factor V was replaced with factor VLEIDEN no differences were observed in the absence of the protein C pathway in thrombin generation in our hemophilia model. This excludes the possibility that factor VLEIDEN has higher intrinsic cofactor activity under hemophilia conditions. Consistent with this, purified factor VLEIDEN possesses the same clotting activity when added to an activated partial thromboplastin time (APTT) assay in the presence of low levels of factor VIII.19
In the presence of the protein C pathway constituents, increased thrombin formation is observed with the factor VLEIDEN mutation. The extent of increase in thrombin generation ranges from threefold to sevenfold in the artificial hemophilia A situation when the concentration of factor VLEIDEN is varied from 50% to 150% of the mean normal plasma factor V concentration. The potential beneficial effect in the hemophilia A situation by factor VLEIDEN, when thrombin generation is surpressed by the protein C pathway, is ~threefold with heterozygous factor VLEIDEN. The increase in thrombin level caused by the factor VLEIDEN mutation in the hemophilia A situation observed in this model provides biochemical data that may explain the reports of beneficial effect of the inheritance of the factor VLEIDEN mutation in severe hemophilia A.
The effects we observed are consistent with the report by Nichols et al.19 The hemophilia A patients studied by Nichols et al in whom factor VLEIDEN appeared to partially compensate for a factor VIII defect, were bearing a factor VIII R1689C or a R2209Q mutation. Patients identified with the same factor VIII mutations, which were homozygous for the normal factor V allele, displayed severe hemorrhagic disease. The factor VIII R1689C mutation occurs at a thrombin cleavage and prevents the formation of active cofactor. The factor VIII R2209Q mutation is located in the C2 domain, which is involved in the lipid binding of the molecule. However, Chan et al30 describe a group of severe hemophiliacs in whom the severity of hemorrhagic symptoms did not correlate with the factor VLEIDEN mutation. Also, Arbini et al31 have reported on the low prevalence of factor VLEIDEN in a cohort of severe hemophiliacs with a hemorrhagic disorder of lesser severity. However, these two studies used a random testing of hemophiliacs for the factor VLEIDEN mutation without correlating specific amino acid substitutions in the factor VIII gene with the presence of factor VLEIDEN, as is the case for the study of Nichols et al.19 However, caution should be employed when generalizing a beneficial effect of factor VLEIDEN in hemophiliacs. Our data show that in an in vitro system factor VLEIDEN will partially compensate for a defective factor VIII molecule. In this respect it should be mentioned that the cases of factor VLEIDEN in hemophilia have been identified by the presence of the mutation at the DNA level. However, this does not necessarily correlate with the plasma levels of the mutant factor V protein, as other factors are involved in the synthesis of factor V. For instance, the inherited combined deficiency of factor V and factor VIII32 has been hypothesized to be the result of a defect in the post-translational process involved in the synthesis of these cofactors. The dependence of the increase in thrombin levels on the concentration of factor VLEIDEN observed in our hemophilia A model suggests that the levels of factor VLEIDEN dictate the degree of a beneficial effect in hemophilia A. Quantitative analyses of factor VLEIDEN at the protein level in the case of hemophilia A may, therefore, shed more light on apparent discrepancies of a beneficial effect of factor VLEIDEN in hemophiliacs. Also, as mentioned by Nichols et al,19 the effect of the factor VLEIDEN mutation may be most pronounced in the context of specific factor VIII mutations.
Hemostatic plugs formed at the end of transected vessels are reported to be more fragile in the case of hemophilia.33,34 The central area of hemostatic plugs formed in hemophilia patients become eroded, and channels are formed, filled with red blood cells through the central area, which are consistent with delayed bleeding.34 Only a rim of fibrin deposition was observed at the periphery of the eroded plugs in hemophiliacs34 in contrast to thick fibrin fibers throughout the stable plugs formed in normal individuals. It should be mentioned that most thrombin is generated in blood after clot formation,35 which is the endpoint characterized in most plasma coagulation tests. Our data suggest that factor VLEIDEN increases and maintains thrombin generation in hemophilic blood by reducing thrombin downregulation by APC. APC-related factor Va fragments are formed during the clotting of whole blood35 without addition of exogenous thrombomodulin, indicating the existence or formation of APC in native blood. Also, hemostatic plugs extend into the lumen of the transected vessels and are in close proximity of thrombomodulin on the endothelium. Thus, APC formation may be expected during the formation of a hemostatic plug, either by endothelial-derived thrombomodulin or by the intrinsic APC generating potential of blood. If APC downregulates thrombin generation during the formation of a hemostatic plug, our data show how the factor VLEIDEN mutation may provide increased fibrin formation or increased stability against fibrinolytic attack36,37 in hemophilia patients.
| |
FOOTNOTES |
Submitted November 27, 1996;
accepted June 5, 1997.
Supported by HL-46703 to K.G.M. and by a TALENT-stipendium of the Netherlands Organization of Scientific Research to C.v.V.
Address reprint requests to Kenneth G. Mann, PhD, Department of Biochemistry, C401 Biven Bldg, The University of Vermont, College of Medicine, Burlington, VT 05405-0068.
The publication costs of this article were defrayed in part by page
charge payment. This article must therefore be hearly marked
``advertisment'' in accordance with 18 U.S.C. section 1734 solely to
indicate this fact.
| |
REFERENCES |
1.
Osterud B,
Rapaport SI:
Activation of factor IX by the reaction product of tissue-factor and factorVII: Additional pathway for initiating coagulation.
Proc Natl Acad Sci USA
74:5260,
1977[Abstract/Free Full Text]
2.
Davie EW,
Fujikawa K,
Kisiel W:
The coagulation cascade: Initiation, maintenance, and regulation.
Biochemistry
30:10363,
1991[Medline]
[Order article via Infotrieve]
3.
Mann KG,
Krishnaswamy S,
Lawson JH:
Surface dependent hemostasis.
Semin Hematol
29:213,
1992[Medline]
[Order article via Infotrieve]
4.
Rapaport SI:
The extrinsic pathway inhibitor: A regulator of tissue factor-dependent blood coagulation.
Thromb Haemost
66:6,
1991[Medline]
[Order article via Infotrieve]
5.
Oslou ST,
Bjork I,
Shore JD:
Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin.
Meth Enzym
222:525,
1993
6.
Tollefsen DM:
Insight into the mechanism of action of heparin cofactor II.
Thromb Haemost
74:1209,
1995[Medline]
[Order article via Infotrieve]
7.
Esmon CT:
Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface.
FASEB J
9:946,
1995[Abstract]
8.
Suzuki K,
Stenflo J,
Dählback B,
Teodorsson B:
Inactivation of human coagulation factor V by activated protein C.
J Biol Chem
258:1914,
1983[Abstract/Free Full Text]
9.
Solymoss S,
Tucker MM,
Tracy PB:
Kinetics of inactivation of membrane-bound factor Va by activated protein C. Protein S modulates factor Xa protection.
J Biol Chem
263:14884,
1988[Abstract/Free Full Text]
10.
Vehar GA,
Davie EW:
Preparation and properties of bovine factor VIII (antihemophilic factor).
Biochemistry
19:401,
1980[Medline]
[Order article via Infotrieve]
11.
Marlar RW,
Kleiss AJ,
Griffin JH:
Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme.
Blood
59:1067,
1982[Free Full Text]
12.
Fulcher CA,
Gardiner JE,
Griffin JH,
Zimmerman TS:
Proteolytic inactivation of human coagulation factor VIII procoagulant protein by activated human protein C and its analogy with factor Va.
Blood
63:486,
1984[Abstract/Free Full Text]
13.
Eaton D,
Rodriguez H,
Vehar GA:
Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity.
Biochemistry
25:505,
1986[Medline]
[Order article via Infotrieve]
14.
Koedam JA,
Meijers JCM,
Sixma JJ,
Bouma BN:
Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor.
J Clin Invest
82:1236,
1988
15.
Berg LP,
Varon D,
Martinowitz U,
Wieland K,
Kakkar VV,
Cooper DN:
Combined factor VIII/factor XI deficiency may cause intra-familial clinical variability in haemophilia A among Askenazi Jews.
Blood Coagul Fibrinolysis
5:59,
1994[Medline]
[Order article via Infotrieve]
16.
Koeleman BPC,
Reitsma PH,
Allaart CF,
Bertina RM:
Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families.
Blood
84:1031,
1994[Abstract/Free Full Text]
17.
Zoller B,
Berntsdotter A,
de Frutos PG,
Dahlback B:
Resistance to activated protein C as an additional risk factor in hereditary deficiency of protein S.
Blood
85:3518,
1995[Abstract/Free Full Text]
18.
Kalafatis M,
Lu D,
Bertina RM,
Long GL,
Mann KG:
Biochemical prototype for familial thrombosis. A study combining a functional protein C mutation and factor Vleiden.
Arterioscl Thromb Vasc Biol
15:2181,
1995[Abstract/Free Full Text]
19.
Nichols WC,
Amano K,
Cacheris PM,
Figueiredo MS,
Michaelides K,
Schwaab R,
Hoyer L,
Kaufman RJ,
Ginsburg D:
Moderation of hemophilia A phenotype by the factor V R506Q mutation.
Blood
88:1183,
1996[Abstract/Free Full Text]
20.
Dahlbäck B,
Carlsson M,
Svensson P:
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a coafactor to activated protein C.
Proc Natl Acad Sci USA
90:1004,
1993[Abstract/Free Full Text]
21.
Bertina R M,
Koeleman BPC,
Koster T,
Rosendaal FR,
Dirven RJ,
de Ronde H,
van der Velden PA,
Reitsma PH:
Mutation in blood coagulation factor V associated with resistance to activated protein C.
Nature
369:64,
1994[Medline]
[Order article via Infotrieve]
22.
Kalafatis M,
Bertina RM,
Rand MD,
Mann KG:
Characterization of the molecular defect in factor VR506Q.
J Biol Chem
270:4053,
1995[Abstract/Free Full Text]
23.
Lawson JH,
Kalafatis M,
Stram S,
Mann KG:
A model for the tissue factor pathway to thrombin, I: An empirical study.
J Biol Chem
269:23357,
1994[Abstract/Free Full Text]
24.
van `t Veer C,
Mann KG:
Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II.
J Biol Chem
272:4367,
1997[Abstract/Free Full Text]
25.
van `t Veer C,
Golden N,
Kalafatis M,
Mann KG:
Inhibitory mechanism of the protein C pathway on tissue factor induced thrombin generation. Synergistic effect in combination with TFPI.
J Biol Chem
272:7983,
1997[Abstract/Free Full Text]
26.
Bajaj SP,
Rapaport SI,
Prodanos C:
A simplified procedure for purification of human prothrombin, factor IX and factor X.
Prep Biochem
11:397,
1981[Medline]
[Order article via Infotrieve]
27.
Katzmann JA,
Nesheim ME,
Hibbard LS,
Mann KG:
Isolation of functional coagulation factor V by using a hybridoma antibody.
Proc Natl Acad Sci USA
78:162,
1981[Abstract/Free Full Text]
28.
Griffith MJ,
Noyes CM,
Church FC:
Reactive site peptide structural similarity between heparin cofactor II and antithrombin III.
J Biol Chem
260:2218,
1985[Abstract/Free Full Text]
29.
Hoyer LW:
Hemophilia A.
N Engl J Med
330:38,
1994[Free Full Text]
30. Chan J, Weinman AF, Thompson AR: Factor V Arg/Gln 506 has no dominant influence on the severity of hemophilia when inherited concurrently. Thromb Haemost 73:1793a, 1995 (suppl 1)
31.
Arbini AA,
Mannucci PM,
Bauer KA:
Low prevalence of the factor V Leiden mutation among "severe" hemophiliacs with a "milder" bleeding diathesis.
Thromb Haemost
74:1255,
1995[Medline]
[Order article via Infotrieve]
32.
Nichols WC,
Seligson U,
Zivelin A,
Terry VH,
Arnold ND,
Siemieniak DR,
Kaufman RJ,
Ginsburg D:
Linkage of combined factors V and VIII deficiency to chromosome 18q by homozygosity mapping.
J Clin Invest
99:596,
1997[Medline]
[Order article via Infotrieve]
33.
Hovig T,
Dodds WJ,
Rowsell HC,
Mustard JF:
The transformation of haemostatic platelet plugs in normal and factor IX deficient dogs.
Am J Pathol
53:355,
1968[Medline]
[Order article via Infotrieve]
34.
Sixma JJ,
van den Berg A:
The haemostatic plug in haemophilia A: A morphological study of haemostatic plug formation in bleeding time skin wounds of patients with severe haemophilia A.
Brit J Heamatol
58:741,
1984[Medline]
[Order article via Infotrieve]
35.
Rand MD,
Lock JB,
van `t Veer C,
Gaffney DP,
Mann KG:
Blood clotting in minimally altered whole blood.
Blood
88:3432,
1996[Abstract/Free Full Text]
36.
Bajzar L,
Manuel R,
Nesheim ME:
Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor.
J Biol Chem
270:14477,
1995[Abstract/Free Full Text]
37.
Bajzar L,
Kalafatis M,
Simioni P,
Tracy PB:
An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden.
J Biol Chem
271:22949,
1996[Abstract/Free Full Text]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Franchini and P. M. Mannucci
Interactions between genotype and phenotype in bleeding and thrombosis
Haematologica,
May 1, 2008;
93(5):
649 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Szlam, T. Taketomi, C. A. Sheppard, C. L. Kempton, J. H. Levy, and K. A. Tanaka
Antithrombin Affects Hemostatic Response to Recombinant Activated Factor VII in Factor VIII Deficient Plasma
Anesth. Analg.,
March 1, 2008;
106(3):
719 - 724.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kurnik, W. Kreuz, S. Horneff, C. During, R. Schobess, C. Bidlingmaier, C. E. Ettingshausen, A. Krumpel, N. Bogdanova, and U. Nowak-Gottl
Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children results of a multicenter study
Haematologica,
July 1, 2007;
92(7):
982 - 985.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Kubisz, J. Stasko, M. Dobrotova, J. Ivankova, and D. Mesko
Severe Hemophilia and Physiologic Inhibitors of Coagulation
Clinical and Applied Thrombosis/Hemostasis,
July 1, 2005;
11(3):
331 - 334.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Castoldi, J. W. P. Govers-Riemslag, M. Pinotti, D. Bindini, G. Tans, M. Berrettini, M. G. Mazzucconi, F. Bernardi, and J. Rosing
Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation
Blood,
December 1, 2003;
102(12):
4014 - 4020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Mann, S. Butenas, and K. Brummel
The Dynamics of Thrombin Formation
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2003;
23(1):
17 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Mann and M. Kalafatis
Factor V: a combination of Dr Jekyll and Mr Hyde
Blood,
January 1, 2003;
101(1):
20 - 30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Corral, J. A. Iniesta, R. Gonzalez-Conejero, M. Villalon, and V. Vicente
Polymorphisms of clotting factors modify the risk for primary intracranial hemorrhage
Blood,
May 15, 2001;
97(10):
2979 - 2982.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Hedner, D. Ginsburg, J. M. Lusher, and K. A. High
Congenital Hemorrhagic Disorders: New Insights into the Pathophysiology and Treatment of Hemophilia
Hematology,
January 1, 2000;
2000(1):
241 - 265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Lenting, J. A. van Mourik, and K. Mertens
The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function
Blood,
December 1, 1998;
92(11):
3983 - 3996.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Laffan and E. Tuddenham
Science, medicine, and the future: Assessing thrombotic risk
BMJ,
August 22, 1998;
317(7157):
520 - 523.
[Full Text]
|
|
|
|
|
Abstract
Introduction
Abstract